Logo image
Bone morphogenetic protein receptor 2 inhibition destabilizes microtubules promoting the activation of lysosomes and cell death of lung cancer cells
Abstract   Open access   Peer reviewed

Bone morphogenetic protein receptor 2 inhibition destabilizes microtubules promoting the activation of lysosomes and cell death of lung cancer cells

Arindam Mondal, Rachel NeMoyer, Mehul Vora, Logan Napoli, Zoya Syed, Elaine Langenfeld, Dongxuan Jia, Youyi Peng, John Gilleran, Jacques Roberge, …
Cell communication and signaling, Vol.19, pp.1-15
09/25/2021
PMID: 34563224

Abstract

Bone Morphogenetic Protein Receptors, Type I - genetics Bone Morphogenetic Protein Receptors, Type II - antagonists & inhibitors Bone Morphogenetic Protein Receptors, Type II - genetics Cell Death - drug effects Cell Death - genetics Cell Proliferation - drug effects Cell Survival - drug effects Humans Imidazoles - pharmacology Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Lysosomes - drug effects Lysosomes - genetics Microtubules - drug effects Microtubules - genetics Naphthoquinones - pharmacology Pyrazoles - pharmacology Pyrimidines - pharmacology Quinolones - pharmacology RNA, Small Interfering - pharmacology Signal Transduction - drug effects
Background: Recent studies have shown that bone morphogenetic protein receptor 2 (BMPR2) regulates cell survival signaling events in cancer cells independent of the BMP type 1 receptor (BMPR1) or the Smad-1/5 transcription factor. Mutations in BMPR2 trafficking proteins leads to overactive BMP signaling, which leads to neurological diseases caused by BMPR2 stabilization of the microtubules. It is not known whether BMPR2 regulates the microtubules in cancer cells and what effect this has on cell survival. It is also not known whether alterations in BMPR2 trafficking effects activity and response to BMPR2 inhibitors. Methods: We utilized BMPR2 siRNA and the BMP receptor inhibitors JL5 and Ym155, which decrease BMPR2 signaling and cause its mislocalization to the cytoplasm. Using the JL5 resistant MDA-MD-468 cell line and sensitive lung cancer cell lines, we examined the effects of BMPR2 inhibition on BMPR2 mislocalization to the cytoplasm, microtubule destabilization, lysosome activation and cell survival. Results: We show that the inhibition of BMPR2 destabilizes the microtubules. Destabilization of the microtubules leads to the activation of the lysosomes. Activated lysosomes further decreases BMPR2 signaling by causing it to mislocalizated to the cytoplasm and/or lysosome for degradation. Inhibition of the lysosomes with chloroquine attenuates BMPR2 trafficking to the lysosome and cell death induced by BMPR2 inhibitors. Furthermore, in MDA-MD-468 cells that are resistant to JL5 induced cell death, BMPR2 was predominately located in the cytoplasm. BMPR2 failed to localize to the cytoplasm and/or lysosome following treatment with JL5 and did not destabilize the microtubules or activate the lysosomes. Conclusions: These studies reveal that the inhibition of BMPR2 destabilizes the microtubules promoting cell death of cancer cells that involves the activation of the lysosomes. Resistance to small molecules targeting BMPR2 may occur if the BMPR2 is localized predominantly to the cytoplasm and/or fails to localize to the lysosome for degradation. Video Abstract.
pdf
Roberge-bone-morphogenetic-protein_VoR3.90 MBDownloadView
Version of Record (VoR) Open Access CC BY V4.0
url
https://doi.org/10.1186/s12964-021-00743-wView
Cell communication and signaling
url
Report an accessibility issueView
Please complete a content remediation request to report an accessibility issue with a library electronic resource, website, or service.

Metrics

150 File downloads
66 Record Views

Details

Logo image